Viral Vector Vaccines
Viral vector vaccines employ non‑replicating or attenuated viral backbones (adenovirus, VSV, MVA) to deliver pathogen antigen genes. They elicit robust CD8+ T‑cell and neutralizing antibody responses, support single‑dose or rapid prime schedules, and can be rapidly reprogrammed for emergent threats—making them a strategic tool for force health protection and outbreak response.
Technical Challenges
Pre-existing anti-vector immunity reducing vaccine efficacy in some populations
Balancing reactogenicity and safety (vector-related inflammation, rare adverse events)
Manufacturing scale-up under GMP and supply chain constraints in austere deployments
Cold-chain and thermostability limits for forward-deployed use
Regulatory complexity for novel or rapidly modified vectors
Emerging Opportunities
Thermostable, lyophilized formulations suitable for prolonged-field-care and austere settings
Standardized potency and immune-assay correlates that predict T‑cell mediated protection
Rapid GMP-compliant manufacturing and fill/finish pipelines for surge capacity
Vector designs that minimize anti-vector immunity while maximizing cross-reactive protection
Validated mucosal delivery approaches to block transmission in crowded or enclosed environments
Current and Emerging Technologies in Viral Vector Vaccines
Adenoviral vector platforms
Well‑characterized vectors (human and chimpanzee adenoviruses) optimized for strong CD8+ responses and scalable cell‑culture manufacturing.
VSV and MVA vectors
Attenuated backbones (vesicular stomatitis virus, modified vaccinia Ankara) suitable for single‑dose immunogenicity and heterologous prime‑boost regimens.
Capsid and antigen engineering
Genetic and protein engineering to improve antigen expression, tissue targeting, and to evade pre‑existing vector neutralization.
Thermostabilization and formulation
Lyophilization, sugar‑matrix stabilization, and dry‑vial technologies to extend shelf life and enable distribution without continuous cold chain.
Rapid, modular manufacturing
Single‑use bioreactors, cell‑free expression, and platformized GMP processes to accelerate batch release and surge production for emergency responses.
Mucosal and needle‑free delivery
Intranasal or aerosolized vectored vaccines designed to induce mucosal IgA and block transmission in deployed units or closed environments.
Importance to Military Medicine
Force readiness and rapid outbreak response
Rapidly reprogrammable platforms allow fast response to emerging biological threats and preserve unit readiness during outbreaks.
Utility in austere and prolonged-field-care settings
Single‑dose or thermostable vectored vaccines reduce logistical burden when evacuation is delayed or cold chain is limited.
Protection against biological threats
Robust cellular immunity addresses pathogens where antibody responses alone are insufficient, including intracellular and novel agents.
Scalable surge capacity for contingency operations
Platform approaches enable accelerated manufacturing and stockpiling for rapid deployment to forward bases or humanitarian missions.
Alignment with the MTEC Mission
Supports MTEC’s DoD focus by accelerating military‑relevant vaccine technologies from concept to field use, emphasizing force health protection and rapid response.
Aligns with MTEC priorities in infectious disease and biodefense through platform innovation, surge manufacturing, and cold‑chain reduction.
Enables dual‑use civilian benefit—pandemic preparedness and public health—while focusing on military logistical and operational constraints.
Dual-Use (Military + Civilian) Applications
Pre-deployment immunization and rapid ring vaccination during outbreaks.
Countermeasure development for select biological threats and surge stockpiling for contingency operations.
Mucosal vectored vaccines to reduce transmission risk in shipboard, submarine, and barracks settings.
Civilian public‑health use in pandemics and endemic disease control—demonstrating dual‑use impact.
Explore MTEC Members with Viral Vector Vaccines Capabilities
MTEC members bring multidisciplinary strengths—vaccine R&D, GMP manufacturing, formulation science, clinical trial networks, and regulatory expertise—that accelerate translation of viral vector vaccines into operational use. Explore member profiles to identify partners with capabilities in vector engineering, thermostabilization, and rapid‑response manufacturing.
104 Members with Viral Vector Vaccines capabilities.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
The Precision Vaccines Program (PVP), based in the Department of Pediatrics at Boston Children’s Hospital, is an academic research initiative dedicated to discovering and developing next-generation vaccines tailored to vulnerable populations. PVP conducts both basic and translational research to create novel vaccines and therapeutics for diseases that disproportionately affect infants, older adults, and immunocompromised individuals. The program brings together experts in vaccinology, clinical trials, immunology, molecular biology, data management, biostatistics, bioinformatics, and systems biology, fostering international collaboration among academia, government, and industry to advance precision medicine in vaccinology.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
BioPharma Connections is an independent, woman-owned consulting firm founded in San Francisco in 2007, providing strategic business development, technical operations, regulatory, product development, and commercialization support to the life sciences industry. Serving pharmaceutical, biotechnology, medical device, and diagnostic companies globally, the firm specializes in facilitating connections between organizations, service providers, CROs, CDMOs, and investors—guiding clients from concept to commercialization, with deep expertise in regulatory compliance, emerging technologies, and diverse therapeutic areas.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Sunflower Therapeutics is a women-owned and led biotechnology public benefit corporation founded in 2018, dedicated to democratizing access to protein manufacturing worldwide. The company develops next-generation, automated, and fully-integrated protein manufacturing solutions that simplify the process from discovery to full-scale biomanufacturing. Their mission is to make high-quality, cost-effective therapeutics, vaccines, and protein-based products accessible globally, especially in low- and middle-income countries, by leveraging innovative technologies, sustainable practices, and intuitive equipment. Sunflower’s vision is to transform the global health landscape by enabling more medicines and protein products to reach patients and consumers everywhere. Their core technologies include efficient microbial hosts, data-driven process development, and modular manufacturing facilities, supporting agile, rapid, and cost-effective production cycles for a wide range of protein-based products.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Founded in 2016, Maxwell Biosciences is a preclinical stage biotechnology company focused on developing innovative therapeutics targeting viruses, bacteria, fungi, and biofilm formations. Utilizing a unique drug-discovery platform, the company aims to create affordable and effective health solutions to combat infectious diseases and enhance healthspan.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
The University of Cincinnati Office of Research is a premier R1 urban research institution dedicated to advancing transformative knowledge and disruptive discoveries that address real-world challenges. Guided by its Research2030 strategic plan, the Office fosters interdisciplinary collaboration, supports innovative research initiatives, and connects industry, government, and community partners with UC's thought leaders. The Office accelerates economic growth and societal impact by investing in key research strengths such as analytics, cyber, robotics, sensors, skin science, adolescence, cancer, digital humanities, infectious diseases, medical devices, neuroscience, smart cities, sustainability, urban futures, and water. With a strong commitment to transparency, compliance, and research security, the Office provides comprehensive support for faculty, students, and staff throughout the research lifecycle, ensuring excellence and integrity in all scholarly activities. Specialized programs and support offices include biosafety, animal care, research integrity, cybersecurity, human research protection, defense research initiatives, government cost compliance, and radiation safety, all designed to uphold the highest standards of ethical, safe, and innovative research. The Office also keeps the community informed and engaged through its monthly 'Findings' newsletter, highlighting impactful research, partnerships, and opportunities.
The Nanovaccine Institute, established at Iowa State University in 2017, is a national transdisciplinary research consortium focused on advancing nano-based technologies to treat and prevent diseases. The institute aims to revolutionize public health outcomes through the design and promotion of nano-based vaccines and therapeutics.

Moberg Analytics
Moberg Analytics – Advanced Brain Monitoring & Critical Care Informatic
Moberg’s platform unifies brain monitoring data for faster, precise treatment of severe brain injuries in military and civilian care.
University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.
Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.